The 2024 Digestive Disease Week (DDW) Annual Meeting will be held on May 18-21 in Washington, D.C., and virtually.
Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI) versus ustekinumab (STELARA) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers
- Additional presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study of risankizumab as a therapy for adults with moderately to severely active ulcerative colitis